Systemic therapy with single agents for advanced or recurrent endometrial carcinoma

  • Tate Thigpen
Part of the Cancer Treatment and Reasearch book series (CTAR, volume 49)


Endometrial carcinoma, now the most common invasive lesion of the female genital tract with over 40,000 cases annually, is regarded as a curable malignancy for several reasons: (1) symptoms in the form of abnormal bleeding occur early in the disease course, (2) the process at diagnosis is usually confined to the corpus of the uterus, (3) a majority of such lesions are well differentiated, and (4) the resultant cure rate from surgery alone is better than 90%. Despite this evidence of success, overall survival figures show that one-third of all patients with endometrial carcinoma recur within five years of diagnosis; most of these die from the malignancy. Until thirteen years ago, no major effort had sought effective systemic therapy for these unfortunate individuals.


Endometrial Cancer Clin Oncol Endometrial Carcinoma Medroxyprogesterone Acetate Marginal Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Vita VT,Jr, Wasserman T, Young RC, et al., 1976. Perspectives and research in gynecologic oncology. Cancer 38:509–525.CrossRefGoogle Scholar
  2. 2.
    Kelley RM, Baker WH, 1960. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264:216–222.CrossRefGoogle Scholar
  3. 3.
    Kohorn E, 1976. Gestagens and endometrial carcinoma. Gynecol Oncol 4:398–411.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonte J, DeCostu JM, Ide P, et al., 1978. Hormonoprophylaxis andhormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 6:60–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Sail S, DiSaia PJ, Morrow CP, Mortel R, Prem K, Thigpen JT, Creasman WT, 1979. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Amer J Obstet Gynecol 135:647–650.Google Scholar
  6. 6.
    Thigpen JT. Personal communication.Google Scholar
  7. 7.
    Piver S, Barlow J, Lurain J, et al., 1980. Medroxyprogesterone acetate (Depo-provera) vs hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45:268–272.PubMedCrossRefGoogle Scholar
  8. 8.
    Billiet G, DeHertogh R, Bonte J, et al., 1982. Estrogen receptors in human uterine adenocarcinoma: Correlation with tissue differentiation, vaginal karyopycnotic index, and effect of progestogen on anti-estrogen treatment. Gynecol Oncol 14:33.PubMedCrossRefGoogle Scholar
  9. 9.
    Creasman WT, McCarty K,Sr, Barton T, et al., 1980. Clinical correlates of estrogen and progesterone binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55:363–370.PubMedGoogle Scholar
  10. 10.
    Ehrlich CE, Young P, Cleary R, 1981. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications. Amer J Obstet Gynecol 141:539–546.Google Scholar
  11. 11.
    Benraad T, Finberg L, Koenders A, et al., 1980. Do estrogen and progesterone receptors in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand 59:155–159.PubMedCrossRefGoogle Scholar
  12. 12.
    Martin P, Rolland P, Ganxamerre M, et al., 1979, Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlation between receptors, histopathologic examinations, and clinical responses under progestin therapy. Int J Cancer 23:321–329.PubMedCrossRefGoogle Scholar
  13. 13.
    McCarty L,Jr, Barton T, Fetter B, et al., 1979. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Amer J Pathol 96:171–182.Google Scholar
  14. 14.
    Jordan VC, 1976. The anti-tumor effect of tamoxifen in the dimethylbenzanthracene-induced rat mammary carcinoma model. In Proceedings of a Symposium on Hormonal Control of Breast Cancer. Alderly Park, Sept 24, pp. 11–17.Google Scholar
  15. 15.
    Hahnel R, Twaddle E, Ratajczak t, 1973. The influence of synthetic antiestrogens on the binding of tritiated estradio-17 beta by cytosols of human uterus and human breast carcinoma. J Steroid Biochem 4:687.PubMedCrossRefGoogle Scholar
  16. 16.
    Lippman M, Bolan G, Huff K, 1976. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595–4601.PubMedGoogle Scholar
  17. 17.
    Swenerton K, 1980. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64:805.PubMedGoogle Scholar
  18. 18.
    Bonte J, Ide P, Billiet G, et al., 1981. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol 11:140.PubMedCrossRefGoogle Scholar
  19. 19.
    Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley HD, 1984. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 68:809–811.PubMedGoogle Scholar
  20. 20.
    DiMarco A, Zunino F, Silvestrini R, Gambarucci C, Gambetto RA, 1971. Interaction of some daunomvrin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol 20:1323–1328.CrossRefGoogle Scholar
  21. 21.
    Kim SH, Kim JH, 1972. Lethal effect of adriamycin on Hela cells. Caner Res 32:323–325.Google Scholar
  22. 22.
    Benjamin RS, 1975. Clinical pharmacology of adriamycin (NSC-123127). Cancer Chemother Rep, Part 3, 6:183–185.Google Scholar
  23. 23.
    Thigpen T, Buchsbaum, Mangan C, Blessing JA, 1979. Phase II trial of adriamycin in the treatment of advanced of recurrent endometrial carcinoma. Cancer Treat Rep 63:21–27.PubMedGoogle Scholar
  24. 24.
    Horton J, Bezz C, Arseneau J, et al., 1978. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62:159–161.PubMedGoogle Scholar
  25. 25.
    Thigpen JT. Personal communication.Google Scholar
  26. 26.
    Roberts JJ, Pascoe JM, 1872. Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (London) 235:282–284.CrossRefGoogle Scholar
  27. 27.
    DeConti RC, Toftness BR, Lange RC, et al., 1973. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33:1310–1315.PubMedGoogle Scholar
  28. 28.
    Thigpen T, Blessing J, Lagasse L, DiSaia P, Homesley H, 1984. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. Amer J Clin Oncol 7:253–256.CrossRefGoogle Scholar
  29. 29.
    Seski J, Edwards C, Herson J, et al., 1982. Cisplatin chemotherapy for disseminted endometrial cancer. Obstet Gynecol 59:225–228.PubMedGoogle Scholar
  30. 30.
    Trope C, Grundsell H, Johnson J, et al., 1980. A phase II study of cisplatinum for recurrent corpus cancer. Eur J Cancer 16:1025–1026.PubMedGoogle Scholar
  31. 31.
    Deppe G, Cohen, C, Bruckner H, 1980. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammineplatinum (II) after intensive prior therapy. Gynecol Oncol 10:51–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Thigpen JT. Personal communication.Google Scholar
  33. 33.
    Wiltshaw E, Evans B, Harland S, 1985. Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV. Proc Amer Soc Clin Oncol 4:121.Google Scholar
  34. 34.
    Pecorelli S, Bolis G, Vassena L, Epis A, Landoni F, Zanaboni F, Vergadoro F, Favalli G, Gambino A, Marsoni S, Torri W, Jannsen N, Mangioni C, 1988. Randomized comparison of cisplatin (P) and carboplatin (C) in advanced ovarian cancer. Proc Amer Soc Clin Oncol 7:136.Google Scholar
  35. 35.
    McGuire WP, Arseneau J, Blessing J, Given F, Hatch K, Creasman W, DiSaia P, Teng N, 1988. Randomized comparison of carboplation (CP) and iproplatin (IP) in advanced squamous carcinoma of the uterine cervix (SCUC): A Gynecologic Oncology Group (GOG) study. Proc Amer Soc Clin Oncol 7:135.Google Scholar
  36. 36.
    Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmondson JH, Buckner JC, 1988. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Instit 80:276–278.CrossRefGoogle Scholar
  37. 37.
    Alberts D. Personal communication.Google Scholar
  38. 38.
    Seski J, Edwards C, Copeland L, et al., 1981. Hexamethylmelamine chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58:361–363.PubMedGoogle Scholar
  39. 39.
    Thigpen JT. Personal communication.Google Scholar
  40. 40.
    Thigpen JT. Personal communication.Google Scholar
  41. 41.
    Slayton R. Personal communication.Google Scholar
  42. 42.
    Salyton R, Faraggi D, 1986. A phase II clinical trial of methyl-glyoxal-bis-guanylhydra-zone (MGBG) in advanced endometrial cancer. Proc Amer Soc Clin Oncol 5:119, 1986.Google Scholar
  43. 43.
    Omura G, Shingleton H, Creasman W, Blessing J, Bornow R, 1978. Chemotherapy of gynecologic cancer with nitrosoureas: A randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina, and vulva. Cancer Treat Rep 62:833–835.PubMedGoogle Scholar
  44. 44.
    Levin L, Hryniuk W, 1987. The use of dose intensity (DI) analysis to solve problems in gynecologic oncology. Proc Amer Soc Clin Oncol 6:119.Google Scholar
  45. 45.
    Thigpen T, Blessing J, Homesley H, Petty W, 1986. Phase II trial of piperazinedione in treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Amer J Clin Oncol 9:21–23.CrossRefGoogle Scholar
  46. 46.
    Slayton R, Blessing J, Delgado G, 1982. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep 66:1669–1671.PubMedGoogle Scholar
  47. 47.
    Stehman F, Blessing J, Delgado G, Louka M, 1983. Phase II evaluation of dianhydrogalac-titol in the treatment of advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 67:737–738.PubMedGoogle Scholar
  48. 48.
    Homesley H, Blessing J, Conroy J, Hatch K, DiSaia P, Twiggs L, 1986. ICRF-159 (Razoxane) in patients with advanced adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Am J Clin Oncol 9:15–17.PubMedCrossRefGoogle Scholar
  49. 49.
    Muss H, Bundy B, DiSaia P, Ehrlich C, 1987. Mitoxantrone for carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 71:217–218.PubMedGoogle Scholar
  50. 50.
    Asbury R. Personal communication.Google Scholar
  51. 51.
    Muss H. Personal communication.Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Tate Thigpen

There are no affiliations available

Personalised recommendations